Portal de Periódicos da CAPES

A Prospective, Split-Face, Randomized, Comparative Study of Safety and 12-Month Longevity of Three Formulations of Hyaluronic Acid Dermal Filler for Treatment of Nasolabial Folds

2012; Lippincott Williams & Wilkins; Volume: 38; Issue: 7 Linguagem: Inglês

10.1111/j.1524-4725.2012.02468.x

1524-4725

Welf Prager, Esther Wissmueller, Isabel Havermann, Eva K. Bee, David J. Howell, I. Zschocke, Jeannette Simon,

Dermatologic Treatments and Research

BACKGROUND Data regarding several hyaluronic acids (HAs) used identically for facial tissue augmentation have heretofore been unavailable. OBJECTIVES This prospective, split-face, randomized, two-armed study sought to determine the long-term safety and effectiveness of three HAs (HA-1 (Belotero Basic/Balance), HA-2 (Restylane), and HA-3 (Juvéderm Ultra 3/Juvéderm Ultra Plus XC) in the treatment of nasolabial folds (NLFs). METHODS Twenty participants in Arm A received HA-1 in one NLF and HA-2 in the other. In Arm B, 20 participants received HA-1 in one NLF and HA-3 in the other. Injection was at visit 2, with follow-up visits at 1, 6, 9, and 12 months. Mean volume of HA was slightly <1.5 mL/NLF. RESULTS Adverse events were unremarkable across all HAs, with injection site erythema being the most frequent adverse event. Mean pretreatment NLF severity rating for both arms was 2.3; at 12 months, mean posttreatment severity rating was 1.5 for HA-1/HA-2 and 1.6 for HA-1/HA-3. Although not statistically significant, participants tended to show a preference for HA-1. CONCLUSION All three HAs provided essentially equivalent results, except for 4-week evenness results, which favored HA-1. Injection volumes of the three HAs were also similar.